NEW YORK (GenomeWeb) – Exact Sciences today reported preliminary fourth quarter revenue of $14 million to $14.5 million, slightly below analyst estimates of $15.9 million. The company also said it expects full-year 2015 revenues of $39 million to $39.5 million.

Exact said it completed 38,000 Cologuard tests during Q4, and about 104,000 tests during the year — 2015 was the first full year of commercialization for the non-invasive colorectal cancer screening test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.